Where trials will be run and eligibility will depend on industry/clinical partners. Unsure what the in/exclusion criteria will be as it seems to be better for early stages and alzheimers isn't the easiest disease to catch early. They may also want to do an NHP (non-human primate) trial before going to humans depending on what side-effects they saw in the mice and weren't mentioned in this news article.